MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Short Interest Down 26.2% in March

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) saw a large drop in short interest in March. As of March 13th, there was short interest totaling 1,816,131 shares, a drop of 26.2% from the February 26th total of 2,460,745 shares. Based on an average daily trading volume, of 1,893,138 shares, the short-interest ratio is currently 1.0 days. Approximately 6.9% of the company’s stock are sold short.

MAIA Biotechnology Trading Down 5.1%

MAIA Biotechnology stock traded down $0.07 during mid-day trading on Friday, hitting $1.31. The company had a trading volume of 2,486,016 shares, compared to its average volume of 1,268,306. MAIA Biotechnology has a 12 month low of $0.87 and a 12 month high of $3.19. The company has a market capitalization of $50.64 million, a PE ratio of -1.90 and a beta of -0.04. The stock’s 50 day moving average price is $1.92 and its two-hundred day moving average price is $1.57.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its quarterly earnings results on Monday, March 23rd. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.05. Equities research analysts anticipate that MAIA Biotechnology will post -1.3 EPS for the current year.

Hedge Funds Weigh In On MAIA Biotechnology

A number of hedge funds have recently added to or reduced their stakes in MAIA. Geode Capital Management LLC lifted its position in MAIA Biotechnology by 9.5% in the 4th quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock valued at $454,000 after acquiring an additional 25,684 shares in the last quarter. Jane Street Group LLC purchased a new stake in MAIA Biotechnology during the 4th quarter valued at $120,000. Marshall Wace LLP bought a new stake in shares of MAIA Biotechnology in the 2nd quarter worth $29,000. Centric Wealth Management increased its holdings in shares of MAIA Biotechnology by 2.0% in the 4th quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock worth $897,000 after purchasing an additional 11,500 shares in the last quarter. Finally, Ritholtz Wealth Management purchased a new position in shares of MAIA Biotechnology in the fourth quarter worth $35,000. 5.65% of the stock is currently owned by hedge funds and other institutional investors.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.